Provided by Tiger Trade Technology Pte. Ltd.

Lantern Pharma Inc.

1.01
-0.0750-6.91%
Post-market: 1.050.0400+3.96%18:32 EDT
Volume:420.70K
Turnover:428.11K
Market Cap:12.89M
PE:-0.62
High:1.16
Open:1.10
Low:0.9700
Close:1.09
52wk High:4.70
52wk Low:0.9700
Shares:12.76M
Float Shares:9.85M
Volume Ratio:1.13
T/O Rate:4.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6362
EPS(LYR):-1.5709
ROE:-400.92%
ROA:-74.29%
PB:-4.01
PE(LYR):-0.64

Loading ...

Sep 24, 2026

Major Issues Report

Form 8-K - Current report
Sep 23, 2026

Major Issues Report

Form 8-K - Current report
Aug 14, 2026

Major Issues Report

Form 8-K - Current report
Aug 14, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 04, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Aug 03, 2026

Major Issues Report

Form 8-K - Current report
Jul 24, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Jun 12, 2026

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Jun 02, 2026

Major Issues Report

Form 8-K - Current report
May 15, 2026

Major Issues Report

Form 8-K - Current report
May 15, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 14, 2026

Major Issues Report

Form 8-K - Current report
Apr 30, 2026

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Apr 10, 2026

Major Issues Report

Form 8-K - Current report
Apr 03, 2026

Beneficial Ownership Change

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Mar 30, 2026

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 30, 2026

Major Issues Report

Form 8-K - Current report
Jan 23, 2026

Major Issues Report

Form 8-K - Current report
Nov 13, 2025

Major Issues Report

Form 8-K - Current report
Nov 13, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]